ACO2 and prostate carcinoma: Thus, while our results support previous evidence of upregulation of mitochondrial aconitase levels during development of prostate cancer, progression to CRPC seems to involve primarily posttranslational regulation of the enzyme, reflecting the differences between the first and the second metabolic shift during the course of prostate cancer evolution.